IL222823A0 - Nuclear receptor binding agents - Google Patents

Nuclear receptor binding agents

Info

Publication number
IL222823A0
IL222823A0 IL222823A IL22282312A IL222823A0 IL 222823 A0 IL222823 A0 IL 222823A0 IL 222823 A IL222823 A IL 222823A IL 22282312 A IL22282312 A IL 22282312A IL 222823 A0 IL222823 A0 IL 222823A0
Authority
IL
Israel
Prior art keywords
receptor binding
binding agents
nuclear receptor
nuclear
agents
Prior art date
Application number
IL222823A
Other languages
English (en)
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of IL222823A0 publication Critical patent/IL222823A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
IL222823A 2010-05-04 2012-11-01 Nuclear receptor binding agents IL222823A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/773,515 US9623021B2 (en) 2007-01-22 2010-05-04 Nuclear receptor binding agents
PCT/US2011/035206 WO2011140228A1 (en) 2010-05-04 2011-05-04 Nuclear receptor binding agents

Publications (1)

Publication Number Publication Date
IL222823A0 true IL222823A0 (en) 2012-12-31

Family

ID=44904060

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222823A IL222823A0 (en) 2010-05-04 2012-11-01 Nuclear receptor binding agents

Country Status (11)

Country Link
US (1) US9623021B2 (enExample)
EP (1) EP2566330A4 (enExample)
JP (2) JP5792799B2 (enExample)
KR (1) KR20130061151A (enExample)
CN (2) CN106420745A (enExample)
AU (1) AU2011248154B2 (enExample)
CA (1) CA2798259A1 (enExample)
IL (1) IL222823A0 (enExample)
MX (1) MX2012012777A (enExample)
RU (1) RU2604666C2 (enExample)
WO (1) WO2011140228A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009007831A (es) * 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20140297314A1 (en) 2011-07-13 2014-10-02 Gino Tutera Systems and methods for calculating patient dosage
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
CA2883711A1 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
PL229743B1 (pl) * 2013-07-30 2018-08-31 Narodowy Instytut Zdrowia Publicznego Panstwowy Zakl Higieny Nowe pochodne kwasu 3,4-dihydroizochinolino-3- karboks ylowego o właściwościach przeciwnowotworowych, sposób ich syntezy, kompozycje farmaceutyczne zawierające te pochodne oraz ich zastosowanie
HRP20201953T1 (hr) * 2013-09-11 2021-04-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
HUE044180T2 (hu) 2014-04-04 2019-10-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril-vegyületek és ezek alkalmazása IRAK4 inhibitorokként
CN104776687B (zh) * 2014-09-05 2017-09-29 山东诚创医药技术开发有限公司 盐酸考来维仑聚合物的干燥方法
EP3206692B1 (en) 2014-10-15 2024-04-03 Corcept Therapeutics Incorporated Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
KR101800876B1 (ko) 2015-10-28 2017-11-27 전남대학교 산학협력단 신규한 디아릴이소퀴놀론 또는 디아릴이소퀴놀린 화합물 및 이를 포함하는 약제학적 조성물
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018129470A1 (en) * 2017-01-09 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
US11419832B2 (en) 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2848356A (en) 1954-08-30 1958-08-19 Phillips Petroleum Co Fungicides, their preparation and use
CA1285951C (en) 1985-10-28 1991-07-09 Raj N. Misra Naphthalenyl- and quinolinyl-amino substituted phenols
US4921941A (en) 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
HU202842B (en) 1988-01-27 1991-04-29 May & Baker Ltd Process for producing new isoquinolinone derivatives and pharmaceutical compositions containing them
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
US5112869A (en) 1989-04-04 1992-05-12 Sloan-Kettering Institute For Cancer Research Substituted 1-phenylnaphthalenes
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
DE69329787T2 (de) 1992-09-28 2001-06-13 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2H)-Isochinoline, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel und ihre Anwendung für die Herstellung eines Arzneimittels zur Behandlung von Herzinsuffizienzen
DE4345266C2 (de) 1993-10-04 1996-12-19 Luitpold Pharma Gmbh Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
IT1307327B1 (it) 1995-09-12 2001-10-30 Smithkline Beecham Spa Derivati idroisochinolinici sostituiti
WO1997030047A1 (en) 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
SE9600769D0 (sv) 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
JP3065949B2 (ja) 1996-09-13 2000-07-17 日本アンテナ株式会社 多周波用アンテナ
HUP0000783A2 (hu) 1996-12-27 2001-04-28 Hoechst Marion Roussel, Inc. N-(piridinil-amino)-izoindolinok és származékaik, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
WO1998051307A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
JP2000072675A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd 医薬組成物
WO2000019994A1 (en) 1998-10-02 2000-04-13 Board Of Trustees Of The University Of Illinois Estrogen receptor ligands
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
WO2000055137A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
CA2378936A1 (en) 1999-08-03 2001-02-08 Abbott Laboratories Potassium channel openers
WO2001022960A1 (en) 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001082923A1 (en) 2000-02-14 2001-11-08 Merck & Co., Inc. Estrogen receptor modulators
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
EP1313700B1 (en) 2000-08-23 2005-11-09 Akzo Nobel N.V. 10-aryl-11h-benzo[b]fluorene derivatives and analogs as estrogenic compounds
US6870055B2 (en) 2000-09-20 2005-03-22 Merck & Co., Inc. Isoquinolinone potassium channels inhibitors
CA2321406A1 (en) 2000-09-29 2002-03-29 The Regents Of The University Of California Restoration of perturbed barrier function by application of antiandrogens
WO2002032373A2 (en) 2000-10-19 2002-04-25 Merck & Co., Inc. Estrogen receptor modulators
EP1339683B1 (en) 2000-11-27 2006-06-14 Merck & Co., Inc. Estrogen receptor modulators
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
WO2002058639A2 (en) 2001-01-23 2002-08-01 Merck & Co., Inc. Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2002072561A1 (en) 2001-01-26 2002-09-19 Smithkline Beecham Corporation Piperazinyltriazines as estrogen receptor modulators
MXPA03006918A (es) 2001-02-02 2004-05-24 Takeda Chemical Industries Ltd Compuestos heterociclicos fusionados.
WO2002088362A2 (en) 2001-04-27 2002-11-07 Bayer Aktiengesellschaft Regulation of human prostaglandin-f synthase 1-like protein
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
EP1387821A2 (en) 2001-05-10 2004-02-11 Merck & Co., Inc. Estrogen receptor modulators
WO2002094790A1 (en) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
DE60216275T2 (de) 2001-05-25 2007-06-21 Schering Corp. Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
US20030119800A1 (en) 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
AU2002355732B2 (en) 2001-08-01 2006-11-09 Merck Sharp & Dohme Corp. Benzimidazo[4,5-f]isoquinolinone derivatives
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
IL161325A0 (en) 2001-11-19 2004-09-27 Lilly Co Eli Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1478631A1 (en) 2001-11-28 2004-11-24 AstraZeneca AB Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6903238B2 (en) 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US6960607B2 (en) 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
US6774248B2 (en) 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
TW200408385A (en) 2001-12-21 2004-06-01 Akzo Nobel Nv Tetrahydrobenzfluorene derivatives
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US6630508B1 (en) 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
AU2003211931A1 (en) 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
WO2003074044A1 (en) 2002-03-01 2003-09-12 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
US20030220377A1 (en) 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CA2489906A1 (en) 2002-06-06 2003-12-18 University Of Rochester Androgen receptor coregulators
DE10230381A1 (de) * 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6893191B2 (en) 2002-07-19 2005-05-17 Creative Pultrusions, Inc. Wale and retaining wall system
AU2003255149A1 (en) 2002-07-24 2004-02-09 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JPWO2004024694A1 (ja) 2002-09-10 2006-01-05 杏林製薬株式会社 ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical Sustained release preparation
US20060183744A1 (en) 2002-09-19 2006-08-17 Rohrer Susan P Method for treating depression and/or anxiety
MXPA05003054A (es) 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
CN1726193A (zh) 2002-10-15 2006-01-25 田纳西大学研究基金会 杂环选择性雄激素受体调节剂及其使用方法
JP4567460B2 (ja) 2002-11-22 2010-10-20 田辺三菱製薬株式会社 イソキノリン化合物及びその医薬用途
AU2003301020A1 (en) 2002-12-20 2004-07-22 Sankyo Company, Limited Isoquinolinone derivatives and their use as therapeutic agents
CA2512049A1 (en) 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
EP1604983A4 (en) 2003-03-17 2008-06-25 Takeda Pharmaceutical Receptor Antagonists
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
DE602004025460D1 (de) 2003-04-21 2010-03-25 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
ATE406373T1 (de) 2003-04-21 2008-09-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
MXPA05012249A (es) 2003-05-16 2006-02-10 Wyeth Corp Derivados de arilcarbaldehido oxima y su uso como agentes estrogenicos.
US7250440B2 (en) 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
CA2539541C (en) 2003-09-23 2010-06-29 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
EP1667982B1 (en) 2003-09-23 2013-07-31 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
EP1667976B1 (en) 2003-09-23 2010-08-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
AU2004279809B2 (en) 2003-10-03 2010-07-15 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
US20070072810A1 (en) 2003-10-03 2007-03-29 Takeda Pharmaceutical Company, Limited Agent for treating diabetes
JP2007512361A (ja) 2003-11-24 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
EP1689767A1 (en) 2003-11-24 2006-08-16 Merck & Co., Inc. Estrogen receptor modulators
EP1689410B1 (en) 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
UA83416C2 (en) * 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
WO2005099700A1 (en) 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
RU2006142683A (ru) 2004-05-04 2008-06-10 Акэдиа Фармасьютикалз Инк. (Us) Соединения с активностью эстрогенных рецепторов
AU2005254949A1 (en) 2004-06-10 2005-12-29 Merck & Co., Inc. Estrogen receptor modulators
WO2006009912A1 (en) 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
EP1773862A1 (en) 2004-06-30 2007-04-18 Merck & Co., Inc. Estrogen receptor modulators
JP2008505095A (ja) 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物
TW200621261A (en) 2004-08-26 2006-07-01 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
JP2008523065A (ja) 2004-12-09 2008-07-03 メルク エンド カムパニー インコーポレーテッド エストロゲン受容体モジュレーター
US20060183652A1 (en) 2004-12-10 2006-08-17 Takashi Fujitsu Lubricating oil composition
EP1835895A2 (en) 2004-12-31 2007-09-26 Aventis Pharmaceuticals Inc. Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
RU2007128819A (ru) 2005-02-16 2009-03-27 Вайет (Us) Применение селективных агонистов бета-рецепторов эстрогена для лучевой или химиотерапии, вызываемой мукозитом или лучевым циститом
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
MX2007012449A (es) 2005-04-06 2007-12-05 Irm Llc Compuestos y composiciones que contienen diaril-amina, y su uso como moduladores de los receptores nucleares de hormonas esteroideas.
US9763961B2 (en) 2005-04-13 2017-09-19 City Of Hope Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
CN101228108A (zh) * 2005-07-21 2008-07-23 利莱恩斯生命科学有限公司 治疗酯酶调节的疾病的化合物
US20070021495A1 (en) 2005-07-25 2007-01-25 Katzenellenbogen John A Sulfonamides as selective estrogen receptor
WO2007012421A1 (en) 2005-07-26 2007-02-01 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
EP1943224B1 (en) 2005-10-05 2011-07-27 Merck Sharp & Dohme Corp. Estrogen receptor modulators
WO2007053353A2 (en) 2005-10-28 2007-05-10 Wyeth Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20070197488A1 (en) 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
AU2007213920B2 (en) 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
RU2008136898A (ru) 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
JP2009526795A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
US8481529B2 (en) 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
EP2035386A1 (en) 2006-06-19 2009-03-18 AstraZeneca AB Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
WO2008016768A1 (en) 2006-08-02 2008-02-07 Roberta Diaz Brinton Phytoestrogenic formulations and uses thereof
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
MX2009007831A (es) 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
US20100029734A1 (en) 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
WO2010096801A1 (en) 2009-02-23 2010-08-26 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy

Also Published As

Publication number Publication date
RU2604666C2 (ru) 2016-12-10
CN106420745A (zh) 2017-02-22
KR20130061151A (ko) 2013-06-10
MX2012012777A (es) 2013-04-24
EP2566330A4 (en) 2013-11-06
JP5792799B2 (ja) 2015-10-14
JP2016006095A (ja) 2016-01-14
US20100267767A1 (en) 2010-10-21
CA2798259A1 (en) 2011-11-10
EP2566330A1 (en) 2013-03-13
AU2011248154A1 (en) 2012-11-29
AU2011248154B2 (en) 2016-03-03
CN102970870A (zh) 2013-03-13
US9623021B2 (en) 2017-04-18
WO2011140228A1 (en) 2011-11-10
JP2013525494A (ja) 2013-06-20
RU2012151846A (ru) 2014-06-10

Similar Documents

Publication Publication Date Title
IL222823A0 (en) Nuclear receptor binding agents
PT2927224T (pt) Antagonistas de receptores
AP2013006764A0 (en) CD33 binding agents
EP2532801A4 (en) fixing
GB201004739D0 (en) Receptor modulators
GB201014577D0 (en) Binder composition
EP2550578A4 (en) ASSOCIATED FILE
GB2502210B (en) Muscle development system
TWM389448U (en) Structure for airbag-squeezing device
ZA201205212B (en) Overforce mechanism
EP2566494A4 (en) CXCR4 RECEPTOR COMPOUNDS
GB201009779D0 (en) Web-winding core
TWM402972U (en) Improved structure for positioning device
GB0913686D0 (en) Criticality based charging
ZA201304156B (en) Imaging agents
PL2397364T3 (pl) Urządzenie do ustalania elementów do zabezpieczania ładunku
GB201009303D0 (en) Fixing device
PL392557A1 (pl) Przyrząd do skakania
TWM402263U (en) Binding machine structure
GB2477090B (en) Securing device
GB201113354D0 (en) Leptin receptor structure
PT2632671E (pt) Agentes molhantes
HK1176233A (en) Nuclear receptor binding agents
TWM389093U (en) Binding device
TWM400980U (en) Binding